GEO for Supplement Brands: Structure-Function Claims That Survive Both the FTC and Summarisation

Ask an AI engine whether magnesium glycinate helps with sleep and read the answer carefully. It will summarise the mechanism, cite two or three sources, and name almost no brands. The sources will be a health publisher, a university health page, and possibly a clinical review. The 40 supplement brands selling magnesium glycinate, several with better ingredient documentation than any of those sources, will not appear.

That is not an accident of ranking. It is what happens when a category with a hard regulatory ceiling writes copy designed to sit just underneath it, and then relies on a disclaimer positioned somewhere else on the page to keep it legal. Summarisation does not carry disclaimers. It carries claims.

This guide covers what actually survives extraction in a regulated category, and why the compliant version of a supplement sentence is consistently the more citable one.

Where Supplement Queries Resolve Now

Three source types own supplement answers, and none of them sell supplements.

Health publishers own the mechanism question. Ask what ashwagandha does and the answer is assembled from consumer health media, because they wrote a structured explainer and brands wrote marketing copy.

Academic and government sources own the evidence question. Ask whether the evidence is any good and the citation goes to a review or a government fact sheet, because those state sample sizes and limitations plainly.

Retailer and aggregator listings own the product question. Ask which one to buy and the answer often comes from a roundup, because roundups compare on attributes while brand pages assert quality.

The brand appears in none of the 3 despite holding information none of them have: the exact form used, the exact dose, the batch test results, and the reasoning behind the formulation. That information is verifiable, which is precisely what a YMYL answer wants and what marketing copy never provides.

The asymmetry is worth sitting with. A publisher writing about magnesium can describe 4 or 5 common forms in general terms. You can state which 1 you use, at what dose, tested by which laboratory, on which lot, on which date. The publisher is being cited and you are not, and the gap is entirely a publishing-format problem rather than a knowledge problem.

Our guide to healthcare and YMYL trust signals covers the broader scrutiny pattern, and supplements sit at the strictest end of it.

The Summarisation Problem With Disclaimers

Here is the specific failure mode, and it is mechanical rather than legal.

A supplement page carries a claim in the body copy and the required FDA disclaimer in the footer or in small print near the buy button. The FDA's label claims guidance requires that disclaimer on structure-function claims, and it does its job on the page.

Then a retrieval system reads the page. It chunks the content, ranks the chunks against the query, and extracts the 1 or 2 passages that answer it. The claim sits in a chunk about the ingredient. The disclaimer sits in a chunk about the site footer. The claim is extracted. The disclaimer is not.

The result is an unqualified assertion attributed to your brand, in an answer you did not write, and which you cannot correct. This is worse than not being cited.

Three consequences follow.

The first is that page-level compliance and passage-level compliance are different standards, and only one of them matters for retrieval. The second is that qualifier placement is now a content design decision, not a legal formality. The third is that engines apply extra caution to health claims, so a page whose passages read as unqualified assertions is more likely to be filtered out than featured, which means the compliance failure and the visibility failure have the same cause.

Our post on content chunking covers how passages get split, and in this category that mechanic has consequences beyond ranking.

Structure-Function Versus Disease Claims

The regulatory line is worth stating precisely, because most brands operate near it without describing it internally.

A structure-function claim describes an effect on normal structure or function in the body. Supports healthy sleep patterns. Helps maintain normal muscle function. These are permitted with the required disclaimer, under the framework the Dietary Supplement Health and Education Act established in 1994, and the FDA expects notification of the claim within 30 days of first marketing it.

A disease claim states or implies that a product treats, prevents, cures or mitigates a disease. Treats insomnia. Reduces anxiety disorder. These convert a supplement into an unapproved drug in the eyes of the regulator, and the FDA's dietary supplement pages make clear that supplements are not approved before marketing and that responsibility for compliance sits with the manufacturer.

The implication line trips more brands than the explicit line. A customer testimonial describing a diagnosed condition, a blog post titled around a disease term, or an ingredient page that lists conditions the ingredient has been studied for can all read as implied claims regardless of the surrounding hedging.

Separately, the FTC's Health Products Compliance Guidance, issued in 2022 to replace advertising guidance that had stood since 1998, governs advertising rather than labelling and sets a substantiation standard: competent and reliable scientific evidence, which for most health claims means randomised, controlled human clinical testing. Two agencies, 2 different standards, and both apply to the same sentence on your website.

Writing the Qualifier Into the Claim

The fix is structural. Make the extractable unit compliant on its own, so that whatever a retrieval system pulls out is a sentence you would be happy to see quoted with no context.

That means the qualifier moves inside the claim sentence.

• Name the population studied rather than implying everyone. In a 12 week trial of adults with low baseline levels is a qualifier that travels with the sentence.
• Name the dose the effect was observed at, because a claim without a dose is not checkable and a claim with one is.
• Name the evidence strength honestly. Studied in 3 small trials totalling under 200 participants, with mixed results, is more credible than a confident assertion, and it is quotable in a way the assertion is not.
• Keep the mechanism and the outcome in the same sentence, so extraction cannot separate the how from the what.
• Avoid the construction where a strong claim is followed by a softening sentence, because chunking may keep the first and drop the second.

Compare the two versions. Supports restful sleep, followed three paragraphs later by a note about study limitations, is a page that is compliant and an extract that is not. Magnesium glycinate at 200 mg has been studied for sleep quality in older adults, with small trials showing modest improvement and larger evidence still limited, is one sentence, compliant standing alone, and considerably more useful to somebody deciding what to buy.

The second version is also the one an engine can actually use, because it contains a form, a dose, a population and an evidence assessment. This is the same inversion we documented in regulated professional services: the sentence that satisfies the regulator is the sentence that satisfies retrieval, because both reward specificity over assertion.

Dose Transparency as the Differentiator

The most competitive thing a supplement brand can publish is its own label, rendered as text.

• Every active ingredient with its exact amount per serving, and the serving size it is per. Per 2 capsules and per 1 capsule are the same formula described in ways that differ by a factor of 2, and shoppers comparing 2 labels rarely check.
• The specific form of each ingredient, since magnesium oxide and magnesium glycinate are not interchangeable and buyers increasingly know it.
• The standardised extract ratio and marker compound where relevant, because a 4 to 1 extract and a 10 to 1 extract are different products at the same milligram figure, and a 5 percent standardisation and a 20 percent standardisation differ by a factor of 4 in the compound that actually does the work.
• Branded or patented ingredients named, since those carry their own research base a reader can look up.
• Other ingredients listed in full, including capsule material, which matters for anyone with a dietary restriction.
• Any proprietary blend broken out as far as you are willing to go, and a plain statement of what you will not disclose and why.

That last item deserves attention. A proprietary blend hides doses, which means no claim about the blend can be evaluated by anyone. A brand that discloses full doses has a genuine advantage and should say so explicitly, comparing its transparency against the category norm rather than asserting quality in the abstract.

Publishing the label as an image is the most common error in the category. An image is invisible to text retrieval, which means the single most differentiating asset on the page contributes nothing to how the page is understood. Render it as an HTML table and keep the image as a visual aid.

Testing, COAs and Verifiable Trust

Third-party testing is the strongest trust artifact available in a category where the FDA does not pre-approve anything.

Publish it properly rather than as a badge.

• The testing laboratory named, not described as an independent third party.
• What was tested for: identity, potency, heavy metals, microbials, pesticides, residual solvents.
• The batch or lot number, with certificates accessible by lot so a customer holding a bottle can check theirs.
• The date of the test, since an undated certificate proves nothing about current stock. A certificate from 2023 sitting on a page selling stock manufactured in 2026 is an accuracy problem wearing the costume of a trust signal.
• Any certification programme with its certifying body and registration detail.
• Manufacturing detail: the facility standard the product is made to, and whether the facility is audited.

Two implementation points matter for retrieval. First, a certificate delivered only as a PDF behind a lookup form is invisible; publish an HTML summary page per batch with the key results in text and link the PDF from it. Second, summarise the results in a sentence a machine can read. Batch 4471, tested 12 March 2026, passed heavy metals at below the reporting limit for lead, arsenic, cadmium and mercury is a fact. Rigorously tested for purity is not.

Who Signs Off and Why It Matters

In YMYL, authorship is not a byline convention, it is an evidence question, and supplements are among the categories where it counts most.

Name a real credentialed person as the reviewer of your health content. A registered dietitian, a pharmacist, a physician, or a PhD in a relevant field. Then make the attribution verifiable.

• A real profile page with credentials, licence detail where applicable, institution and publication history. 1 well-built profile page does more than 10 bylines pointing nowhere.
• A reviewed-on date, distinct from the published date, so the review is anchored in time.
• External corroboration: a professional registry, an institutional page, a research profile.
• Consistency of that identity across every page they review, so the entity resolves rather than fragmenting.

The distinction that matters is between a reviewer who exists and a reviewer who is decoration. A named pharmacist with a verifiable licence and 6 reviewed articles is an authority signal. A stock photograph captioned as a wellness expert is worse than no reviewer at all, because it invites the question of what else is invented. Our guides to E-E-A-T and author authority cover how these signals get evaluated.

The same logic governs reviews. Fabricated or incentivised testimonials in a health category are both a compliance exposure and a retrieval liability, and our post on synthetic reviews covers the patterns that get detected.

Citing Research Properly

Studies show is the least persuasive phrase in supplement marketing and the least extractable.

Cite the way a review paper cites.

• Link the study itself, not a press release or a summary of it.
• State the design: randomised controlled, open label, observational, animal, in vitro. These are not equivalent and treating them as equivalent is the tell of a brand that has not read them.
• State the sample size, because 22 participants and 400 participants support different confidence, and a 6 week trial and a 12 month trial answer different questions.
• State the dose used and whether it matches the dose in your product, which is frequently where the argument quietly falls apart.
• State the funding source, including when it is you.
• State the limitations. A brand that names the weaknesses of its own evidence base reads as credible, and that honesty is exactly the kind of passage engines quote.

The cost of doing this is that some claims will not survive contact with their own evidence. That is the point. A claim that cannot survive a plain description of the study behind it is a claim that was going to be a problem eventually, and finding out during content review is cheaper than finding out in a regulatory letter.

Doing this well also produces the kind of asset covered in our post on original data as citation bait, because a brand that commissions even a small study and publishes it fully has produced something no aggregator can copy.

The Interaction Content Nobody Writes

Here is a real gap. People ask constantly whether they can take a supplement alongside a medication, with another supplement, during pregnancy, or before surgery. Almost no brand answers, because answering feels like inviting risk.

The answer is being given anyway, by health publishers and forums, without your product's specifics.

Content that can be written responsibly:

• Known interactions documented in the literature, cited, with a clear instruction to consult a clinician.
• Timing and absorption guidance, including what to take with food and what competes for absorption.
• Stacking questions, meaning which of your own products are designed to be taken together and which duplicate an ingredient.
• Populations who should seek advice first, stated plainly rather than buried.
• Upper limits and what is known about exceeding them, with the figure stated rather than described as high.
• What to do about a missed dose, which is asked far more than brands expect.

The framing that makes this safe is consistent: describe what the literature documents, cite it, and direct decisions to a clinician. That is informational content, not a claim, and it is the single largest uncovered surface in the category.

Common Mistakes

• Disclaimer in the footer only. Page-level compliance does not survive passage-level extraction.
• Claim and qualifier in different paragraphs. Chunking can keep one and drop the other, and it will keep the claim.
• Supplement facts published as an image. The most differentiating asset on the page, invisible to retrieval.
• Proprietary blends without a stated rationale. Undisclosed doses make every claim unevaluable.
• Studies show with no study. Unquotable, unverifiable, and a signal of weak substantiation.
• A reviewer who cannot be verified. Worse than no reviewer, because it raises a question about everything else.
• Certificates behind a PDF lookup form. Invisible. Publish an HTML summary per batch.
• Silence on interactions. The question gets answered by somebody else, without your product in it.

Implementation Sequence

1. Audit every health claim on the site, typically 30 to 60 sentences across product and blog pages, and rewrite each so the qualifier sits inside the claim sentence.
2. Render supplement facts as an HTML table with exact forms, doses and serving sizes.
3. Publish batch-level certificates as HTML summary pages with the laboratory, date, panel and results in text.
4. Name a credentialed reviewer, build a verifiable profile, and add reviewed-on dates.
5. Replace every studies show with a proper citation carrying design, sample size, dose and limitations.
6. Build the interaction, timing and stacking library with clinician-referral framing throughout.
7. State your transparency position explicitly against the category norm rather than asserting quality.
8. Re-check the rewritten claims against both the FDA labelling rules and the FTC substantiation standard, since they are different tests.

Frequently Asked Questions

Why do AI engines cite health publishers instead of supplement brands?

Because publishers write structured, qualified explanations while brands write assertions. A YMYL answer favours passages that state mechanism, dose and evidence strength honestly, and most brand copy states none of the three. The information advantage sits with the brand, but it is usually published in a form retrieval cannot use.

Where should the FDA disclaimer go if the footer is not enough?

Keep it in the footer for labelling purposes and additionally build the qualifier into each claim sentence. The footer disclaimer satisfies the page requirement; the in-sentence qualifier is what survives extraction. They serve different purposes and you need both.

Does publishing full doses help competitors copy the formula?

Full doses are already on the physical label, so the formula is not secret from anyone who buys one bottle. What non-disclosure actually costs you is the ability to make any evaluable claim, and the transparency comparison against brands using proprietary blends is a genuine differentiator worth stating.

Is it safe to publish content about drug interactions?

Describing what the published literature documents, citing it, and directing the decision to a clinician is informational content rather than a claim. The alternative is that the question is answered by a third party with no knowledge of your specific formulation, which serves nobody.

How much does a named reviewer actually matter?

In YMYL it is one of the strongest available signals, and it must be verifiable. A credentialed reviewer with a real profile, a licence or registry entry and a consistent identity across the site is an authority signal; an unverifiable one undermines the trust of every other page they appear on.